Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for TFRC returned no results
Showing 1801 to 1850 of 2486 results for term

  1. Diabetes in pregnancy (QS109)

    This quality standard covers managing diabetes and its complications in women who are planning a pregnancy or are already pregnant. It includes care for women with pre-existing diabetes before and during pregnancy, and diagnosis and management of gestational diabetes. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    10 January 2023
    View quality statements

    Sections for QS109

  2. Repetitive transcranial magnetic stimulation for depression (HTG396)

    Evidence-based recommendations on repetitive transcranial magnetic stimulation for depression. This involves placing an electromagnetic coil against the scalp, which creates electric currents in certain parts of the brain.

    HealthTech guidance
    Published
    16 December 2015
    View recommendations

    Sections for HTG396

  3. The evidence on the safety of reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia shows there are serious but well-recognised complications. The evidence on efficacy is limited in quantity and quality. Therefore, this procedure should not be used unless  special arrangements   are in place for clinical governance, consent, and audit or research.

    synthetic or biological mesh used, mesh-associated complications and long-term outcomes (at least 3 years). In participating centres,...

    Research recommendation
    Published
    15 November 2019

  4. Organisation of care:- What is the clinical and cost effectiveness of alternative approaches to organising primary care compared with usual care for people with multimorbidity?

    multiple providers or services involved in their care, people with both long-term physical and mental health problems, people with...

    Research recommendation
    Published
    18 October 2016

  5. Further research on aortic valve reconstruction with processed bovine pericardium should address patient selection and report long-term outcomes, particularly the durability of the valve.

    processed bovine pericardium should address patient selection and report long-term outcomes, particularly the durability of the valve....

    Research recommendation
    Published
    13 November 2018

  6. Acne vulgaris: management (NG198)

    This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.

    NICE guideline
    Last updated
    30 April 2026
    View recommendations

    Sections for NG198

  7. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA199

  8. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)

    Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.

    HealthTech guidance
    Published
    23 February 2022
    View recommendations

    Sections for HTG610

  9. Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

    Evidence-based recommendations on pemetrexed for treating malignant pleural mesothelioma in adults.

    Technology appraisal guidance
    Published
    23 January 2008
    View recommendations

    Sections for TA135

  10. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTG695)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.

    HealthTech guidance
    Published
    27 September 2023
    View recommendations

    Sections for HTG695

  11. Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)

    Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.

    Technology appraisal guidance
    Published
    26 November 2014
    View recommendations

    Sections for TA323

  12. GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

    HealthTech guidance
    Published
    3 April 2024
    View recommendations

    Sections for HTG716

  13. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  14. The effect of injectable contraceptives on bone mineral density in women who have used DMPA for longer than 2 years is uncertain. Adequately powered surveys or cross‑sectional studies are needed to examine the recovery of bone mineral density after discontinuation of DMPA after long‑term and very long‑term use. Studies are also needed to examine the risk of bone fractures in older women.

    of bone mineral density after discontinuation of DMPA after long‑term and very long‑term use. Studies are also needed to...

    Research recommendation
    Published
    25 October 2019

  15. OSNA for colon cancer staging (MIB77)

    NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging

    Medtech innovation briefing
    Published
    24 August 2016

  16. Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    report details of patient selection, including size of prostate, and longer-term outcomes, including the need for reintervention. Source...

    Research recommendation
    Published
    30 September 2022

  17. Evidence on the efficacy and safety of neurostimulation of lumbar muscles for refractory non-specific chronic low back pain is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    appropriate duration. It should report details of patient selection and long-term outcomes. Source guidance details Comes from guidance...

    Research recommendation
    Published
    30 September 2022

  18. Effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse:- What is the effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse in the UK?

    Primary outcomes of interest include a direct measure of drug use. Longer term outcomes (longer than 1 year) from longitudinal studies...

    Research recommendation
    Published
    4 May 2017

  19. Behaviour change: digital and mobile health interventions (NG183)

    This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.

    NICE guideline
    Published
    7 October 2020
    View recommendations

    Sections for NG183

  20. NICE indicator process guide (PMG44)

    This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence

  21. Use of NICE content in the UK

    and the British National Formulary (BNF and BNFc) are not covered by the terms of this licence. Please contact licensing@rpharms.com for...

  22. What is the clinical and cost effectiveness of humeral hemiarthroplasty compared with conventional total shoulder replacement for adults aged under 60 having primary elective shoulder replacement for osteoarthritis with no rotator cuff tear?

    increasingly being offered to people aged under 60 as confidence grows in its long-term durability. There is a lack of evidence in this...

    Research recommendation
    Published
    10 August 2020

  23. Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (TA908)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    5 July 2023
    View recommendations

    Sections for TA908

  24. Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)

    Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

    Evidence summary
    Published
    8 July 2014

  25. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

    Medtech innovation briefing
    Published
    11 March 2016

  26. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.

    NICE guideline
    Last updated
    8 March 2024

    Sections for NG122

  27. The role of parents in the treatment of children and young people with social anxiety disorder:- What is the best way of involving parents in the treatment of children and young people (at different stages of development) with social anxiety disorder?

    example, group CBT) as the comparison. It should report short- and medium-term outcomes (including cost effectiveness) with a follow-up...

    Research recommendation
    Published
    9 June 2015

  28. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.

    Technology appraisal guidance
    Published
    26 March 2025
    View recommendations

    Sections for TA1050

  29. Clinical call handlers:- What is the most clinically and cost-effective use of clinical call handlers in a telephone advisory service in terms of i) the ratio of clinical to non-clinical call handlers and ii) point of access to clinical call handlers in a telephone advisory service pathway? [See the evidence review on non-emergency telephone access and call handlers.]

    cost-effective use of clinical call handlers in a telephone advisory service in terms of i) the ratio of clinical to non-clinical call...

    Research recommendation
    Published
    15 November 2018

  30. Current evidence on the safety of ultrasound-guided high‑intensity transcutaneous focused ultrasound for symptomatic uterine fibroids shows there are well-recognised complications including skin burns. The evidence on efficacy is limited in quality. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    location and number of fibroids), patient-reported outcome measures, long-term outcomes and subsequent pregnancy rates. Source guidance...

    Research recommendation
    Published
    15 November 2019

  31. Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid) and tocilizumab (RoActemra) for treating COVID-19.

    Technology appraisal guidance
    Last updated
    26 February 2026
    View recommendations

    Sections for TA878

  32. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)

    Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.

    Technology appraisal guidance
    Published
    23 January 2025
    View recommendations

    Sections for TA1035

  33. Immunosuppressive therapy for kidney transplant in children and young people (TA482)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

    Technology appraisal guidance
    Published
    11 October 2017
    View recommendations

    Sections for TA482

  34. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.

    Technology appraisal guidance
    Published
    17 October 2019
    View recommendations

    Sections for TA607

  35. Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)

    Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.

    HealthTech guidance
    Published
    27 August 2025
    View recommendations

    Sections for HTG759

  36. Mental health of adults in contact with the criminal justice system (QS163)

    This quality standard covers recognising, assessing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system (this includes police contact, court and prison custody, street triage, liaison and diversion services, and probation services). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    9 February 2018
    View quality statements

    Sections for QS163

  37. Motor neurone disease (QS126)

    This quality standard covers assessing and managing motor neurone disease, including care, support and planning after diagnosis. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    27 July 2016
    View quality statements

    Sections for QS126

  38. Do needle and syringe programmes have any unintended consequences: Do they increase the uptake, frequency and length of injecting drug use? Does the provision of disposal facilities (for example, drop-boxes) affect the amount of drug-related litter in an area? Do they have a negative impact on the local community, for example, in terms of crime rates or the fear of crime?

    Do they have a negative impact on the local community, for example, in terms of crime rates or the fear of crime? Any explanatory...

    Research recommendation
    Published
    9 June 2015

  39. Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)

    Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

    Technology appraisal guidance
    Published
    28 July 2021
    View recommendations

    Sections for TA716

  40. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

    Technology appraisal guidance
    Published
    26 June 2013
    View recommendations

    Sections for TA290

  41. The evidence for treating an acute migraine attack is adequate but, for treating subsequent attacks, is limited in quality and quantity. So, for treating acute migraine, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page . The evidence for preventing migraine is inadequate in quality. So, for preventing migraine, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    and severity of migraine episodes, quality of life in the short and long term, any changes in medication and management of subsequent...

    Research recommendation
    Published
    7 November 2022

  42. Mobi-C for cervical disc replacement (MIB70)

    NICE has developed a medtech innovation briefing (MIB) on Mobi-C for cervical disc replacement

    Medtech innovation briefing
    Published
    28 June 2016

  43. Oral health in care homes (QS151)

    This quality standard covers oral health, including dental health and daily mouth care, for adults in care homes (with and without nursing provision). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    7 June 2017
    View quality statements

    Sections for QS151

  44. Oesophago-gastric cancer (QS176)

    This quality standard covers assessing and managing oesophago-gastric cancer in adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    13 December 2018
    View quality statements

    Sections for QS176

  45. Learning disability: identifying and managing mental health problems (QS142)

    This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.

    Quality standard
    Published
    10 January 2017
    View quality statements

    Sections for QS142

  46. Biopatch for venous or arterial catheter sites (MIB117)

    NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .

    Medtech innovation briefing
    Published
    9 August 2017

  47. Tests in secondary care to identify people at high risk of ovarian cancer (HTG453)

    Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.

    HealthTech guidance
    Published
    15 November 2017
    View recommendations

    Sections for HTG453

  48. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

    Technology appraisal guidance
    Published
    25 March 2015
    View recommendations

    Sections for TA336

  49. Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)

    Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.

    Technology appraisal guidance
    Published
    31 January 2024
    View recommendations

    Sections for TA948

  50. COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Withdrawn advice